Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to tackle rare blood cancer

NCT ID NCT02232516

Completed Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested whether combining two drugs, romidepsin and lenalidomide, is safe and effective for people with peripheral T-cell lymphoma (PTCL) who haven't had treatment yet. PTCL is a rare blood cancer with no standard therapy, and current options like CHOP chemotherapy are often hard to tolerate. The study enrolled 30 adults with various PTCL subtypes and measured how many patients responded to treatment, as well as any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
romidepsin and lenalidomide
What this could lead to
If successful, this combination could offer a more effective and tolerable treatment option for people with peripheral T-cell lymphoma who have not been treated before.
What could go wrong
This is a small, early-phase study with only 30 participants. The combination may cause significant side effects, and results may not apply to all types of PTCL.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ALK-negative anaplastic large cell lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma enteropathy-associated T-cell lymphoma extranodal nasal NK/T cell lymphoma hepatosplenic T-cell lymphoma Lymphoma, Extranodal NK-T-Cell mature T-cell and NK-cell non-Hodgkin lymphoma mycosis fungoides peripheral T-cell lymphoma, not otherwise specified primary cutaneous T-cell non-Hodgkin lymphoma Sezary syndrome subcutaneous panniculitis-like T-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA ANAPLASTIC LARGE CELL LYMPHOMA ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA HEPATOSPLENIC T-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IA MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE IB MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IIA MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE IIB MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IIIA MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE IIIB MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA STAGE IVA MYCOSIS FUNGOIDES/SEZARY SYNDROME STAGE IVB MYCOSIS FUNGOIDES/SEZARY SYNDROME

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

    Seattle, Washington, 98109, United States

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Weill Cornell Medicine

    New York, New York, 10021, United States

  • Yale University

    New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.